Visit https://www.peervoice.com/VYU860 to view the entire programme with slides. After completing “Novel Therapies for Patients With DLBCL: What Does the Future Hold?”, participants will be able to: Explain the rationale for novel therapeutic options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Evaluate the risk-benefit profiles of current and emerging therapies for the management of R/R DLBCL; and Incorporate available data on the use of novel anti-CD19 antibody strategies to treat R/R DLBCL into clinical practice.

Visit https://www.peervoice.com/QTK860 to view the entire programme with slides. After completing “New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.

Visit https://www.peervoice.com/QSX860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

Visit https://www.peervoice.com/ZFC860 to view the entire programme with slides. After completing “Mapping New Blueprints for Lung Cancer Care: Congress Updates in NSCLC and ES-SCLC”, participants will be able to: Evaluate the latest evidence for the adjuvant treatment of EGFR-mutated non-small-cell lung cancer (NSCLC); and Outline key updates on the use of immunotherapy in the management of extensive-stage small cell lung cancer (ES-SCLC).

Visit https://www.peervoice.com/YZK860 to view the entire programme with slides. After completing “Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

Visit https://www.peervoice.com/GPA860 to view the entire programme with slides. After completing “Wake Up and Smell the Coffee: Kicking Into Play Novel Treatment Options for Nasal Polyposis”, participants will be able to: Summarise the benefits and limitations associated with standard of care treatment options for managing nasal polyposis in patients with chronic rhinosinusitis; Analyse recent clinical trial data associated with current and emerging biologic therapies for the management of patients with chronic rhinosinusitis and nasal polyposis; and Develop individualised treatment plans for patients with chronic rhinosinusitis and nasal polyposis who are eligible for add-on biologic therapy.

Visit https://www.peervoice.com/RGZ860 to view the entire programme with slides. After completing “Clearing the Path Forward for Cancer-Associated VTE Treatment: The Role of Direct Oral Anticoagulants in Canadian Practice”, participants will be able to: Discuss the latest evidence with direct oral anticoagulants (DOACs) for the management of cancer-associated venous thromboembolism (VTE); and Outline optimal clinical use of DOACs in cancer-associated VTE, based on the data and recent guideline recommendations.

Visit https://www.peervoice.com/YJF860 to view the entire programme with slides. After completing “The Evolving Role of AR-Targeted Agents in Prostate Cancer: A Window of Opportunity to Maximize Outcomes”, participants will be able to: Identify the clinical implications of the most recent data evaluating androgen receptor (AR)-targeted agents in metastatic castration-sensitive prostate cancer (mCSPC); Define which patients with mCSPC should be considered for treatment with AR-targeted agents; and Formulate a therapeutic treatment plan for patients with prostate cancer on AR-targeted agents that balances efficacy and safety.

Visit https://www.peervoice.com/KHF860 to view the entire programme with slides. After completing “Can We Tip the Scale Towards Better Outcomes in CLL Treatment? The Experts Weigh In”, participants will be able to:

Visit https://www.peervoice.com/XYD860 to view the entire programme with slides. After completing “Flipping the Script on Genetic Diseases: Understanding and Applying Gene Therapy to Change Patient Outcomes”, participants will be able to: Differentiate key strategies in gene therapy and how they may impact the management of genetic diseases; and Discuss the applicability of gene replacement therapy in the management of monogenic diseases.